[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sagimet Biosciences Inc Series A (SGMT)

Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 331,715
  • Shares Outstanding, K 32,585
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,040 K
  • EBIT $ -53 M
  • EBITDA $ -53 M
  • 60-Month Beta 3.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.35

Options Overview Details

View History
  • Implied Volatility 72.53% (-0.61%)
  • Historical Volatility 72.79%
  • IV Percentile 1%
  • IV Rank 0.62%
  • IV High 322.38% on 01/28/26
  • IV Low 70.97% on 08/17/26
  • Expected Move (DTE 28) 1.39 (13.44%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 289
  • Volume Avg (30-Day) 596
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 17,777
  • Open Int (30-Day) 11,327
  • Expected Range 8.92 to 11.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 4
  • High Estimate $-0.20
  • Low Estimate $-0.28
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.50 +58.62%
on 08/03/26
11.15 -7.53%
on 08/17/26
+3.24 (+45.83%)
since 07/21/26
3-Month
6.24 +65.22%
on 06/16/26
11.15 -7.53%
on 08/17/26
+3.31 (+47.29%)
since 05/21/26
52-Week
4.50 +129.11%
on 03/30/26
11.15 -7.53%
on 08/17/26
+2.96 (+40.27%)
since 08/21/25

Most Recent Stories

More News
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

FOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences: Whether the Burn Rate Narrative Shifts or Solidifies

Barchart Research What to Expect from SGMT Earnings SGMT Generated August 11, 2026 Current Price $9.52 EPS Estimate $$-0.28 Consensus Rating Strong Buy Average Move 5.69% Sagimet Biosciences: Whether the...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S.  on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH

Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 10.25 (+0.69%)
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of...

SGMT : 10.25 (+0.69%)

Business Summary

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.

See More

Key Turning Points

3rd Resistance Point 10.98
2nd Resistance Point 10.81
1st Resistance Point 10.49
Last Price 10.25
1st Support Level 10.01
2nd Support Level 9.84
3rd Support Level 9.52

See More

52-Week High 11.15
Last Price 10.25
Fibonacci 61.8% 8.61
Fibonacci 50% 7.82
Fibonacci 38.2% 7.04
52-Week Low 4.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.